Average Co-Inventor Count = 8.34
ph-index = 6
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Hoffmann-la Roche Inc. (10 from 4,945 patents)
2. Roche Glycart Ag (8 from 68 patents)
3. Engmab Sarl (4 from 5 patents)
4. Roche Glyeart Ag (1 from 3 patents)
5. Engmab Ag (1 from 1 patent)
6. F. Hoffmann-la Roche Ag (168 patents)
7. Engmab Beta Holdings LLC (0 patent)
24 patents:
1. 12286486 - Anti-FAP antibodies and methods of use
2. 12139553 - T cell activating bispecific antigen binding molecules
3. 11718680 - Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
4. 11459404 - Bispecific T cell activating antigen binding molecules
5. 11332545 - Anti-FAP antibodies and methods of use
6. 11117965 - Bispecific T cell activating antigen binding molecules
7. 11013801 - Treatment method
8. 10882918 - Bispecific T cell activating antigen binding molecules
9. 10851171 - Method for the selection of antibodies against BCMA
10. 10781257 - Bispecific T cell activating antigen binding molecules
11. 10781258 - Bispecific T cell activating antigen binding molecules
12. 10766967 - Bispecific T cell activating antigen binding molecules
13. 10683369 - Monoclonal antibodies against BCMA
14. 10611840 - Bispecific T cell activating antigen binding molecules
15. 10611841 - Bispecific T cell activating antigen binding molecules